Daiichi Sankyo Completes Phase II, Moves To Phase III With Oral Factor Xa Inhibitor

TOKYO - Daiichi Sankyo said Dec. 8 that it would soon complete Phase II clinical trials of its oral Factor Xa inhibitor DU-176b, after it registered comparable safety and tolerability in non-valvular atrial fibrillation patients compared to those taking the anticoagulant warfarin